Ivermectin and diethylcarbamazine trials in leaf monkeys (Presbytis cristatus) infected with Wuchereria kalimantani

Southeast Asian J Trop Med Public Health. 1992 Jun;23(2):288-92.

Abstract

Clinical trials of Ivermectin in single oral doses of 200, 400, and 1,000 mg/kg body weight or in multiple doses of 200 mg/kg body weight for 5 consecutive days were performed in leaf monkeys (Presbytis cristatus) infected with Wuchereria kalimantani. Optimal microfilaricidal effect occurred at 200 mg/kg body weight. The drug was less effective than diethylcarbamazine in this animal model for human filariasis but had no adverse effects.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cercopithecidae
  • Diethylcarbamazine / administration & dosage
  • Diethylcarbamazine / pharmacology
  • Diethylcarbamazine / therapeutic use*
  • Haplorhini
  • Ivermectin / administration & dosage
  • Ivermectin / pharmacology
  • Ivermectin / therapeutic use*
  • Microfilariae
  • Parasitic Diseases / drug therapy*
  • Placebos
  • Wuchereria / drug effects*

Substances

  • Placebos
  • Ivermectin
  • Diethylcarbamazine